5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

5-Hydroxytryptamine Receptor 7 (5-HT7) plays an important role in autistic disorder and other neuropsychiatric disorders. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.

The 5-HT7 pipeline market research report provides comprehensive information on the 5-HT7 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research, and development history as well as the latest news and press releases. Additionally, the report provides an overview of key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics development with respective active and dormant or discontinued projects.

Key Therapy Areas in the 5-HT7 Pipeline Products Market

The key therapy areas in the 5-HT7 pipeline products market are the central nervous system, cardiovascular, gastrointestinal, and respiratory.

5-HT7 Pipeline Products Market Analysis by Therapy Areas

5-HT7 Pipeline Products Market Analysis by Therapy Areas

For more therapy area insights, download a free report sample

Key Mechanisms of Action in the 5-HT7 Pipeline Products Market

The key mechanisms of action in the 5-HT7 pipeline products market are 5-Hydroxytryptamine Receptor 7 Antagonist and 5-Hydroxytryptamine Receptor 7 Agonist.

5-HT7 Pipeline Products Market Analysis by Mechanisms of Action

5-HT7 Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights, download a free report sample

Key Routes of Administration in the 5-HT7 Pipeline Products Market

The key routes of administration in the 5-HT7 pipeline products market are oral, intramuscular, intravenous, and sublingual.

5-HT7 Pipeline Products Market Analysis by Routes of Administration

5-HT7 Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the 5-HT7 Pipeline Products Market

The key molecule type in the 5-HT7 pipeline products market is small molecule.

Major Companies in the 5-HT7 Pipeline Products Market

Some of the major companies in the 5-HT7 pipeline products market are Adamed Pharma SA, Avineuro Pharmaceuticals Inc, Celon Pharma SA, Core One Labs Inc, Daya Drug Discoveries Inc, H. Lundbeck AS, Johnson & Johnson, LB Pharmaceuticals Inc, Praeventix LLC, and Reviva Pharmaceuticals Inc.

5-HT7 Pipeline Products Market Analysis by Companies

5-HT7 Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

5-HT7 Pipeline Products Market Report Overview

Key Therapy Areas Central Nervous System, Cardiovascular, Gastrointestinal, and Respiratory
Key Mechanisms of Action 5-Hydroxytryptamine Receptor 7 Antagonist and 5-Hydroxytryptamine Receptor 7 Agonist
Key Routes of Administration Oral, Intramuscular, Intravenous, and Sublingual
Key Molecule Type Small Molecule
Major Companies Adamed Pharma SA, Avineuro Pharmaceuticals Inc, Celon Pharma SA, Core One Labs Inc, Daya Drug Discoveries Inc, H. Lundbeck AS, Johnson & Johnson, LB Pharmaceuticals Inc, Praeventix LLC, and Reviva Pharmaceuticals Inc

Scope

  • The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)
  • The report reviews 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing, and collaboration details & other developmental activities
  • The report reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics and enlists all their major and minor projects
  • The report assesses 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews the latest news and deals related to 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
  • Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding the 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Adamed Pharma SA
Avineuro Pharmaceuticals Inc
Celon Pharma SA
Core One Labs Inc
Daya Drug Discoveries Inc
H. Lundbeck AS
Johnson & Johnson
LB Pharmaceuticals Inc
Praeventix LLC
Reviva Pharmaceuticals Inc
Sumitomo Pharma Co Ltd
Sunovion Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) – Overview

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) – Companies Involved in Therapeutics Development

Adamed Pharma SA

Avineuro Pharmaceuticals Inc

Celon Pharma SA

Core One Labs Inc

Daya Drug Discoveries Inc

H. Lundbeck AS

Johnson & Johnson

LB Pharmaceuticals Inc

Praeventix LLC

Reviva Pharmaceuticals Inc

Sumitomo Pharma Co Ltd

Sunovion Pharmaceuticals Inc

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) – Drug Profiles

5HT7 Agonist – Drug Profile

Product Description

Mechanism Of Action

ADN-1184 – Drug Profile

Product Description

Mechanism Of Action

ADN-3662 – Drug Profile

Product Description

Mechanism Of Action

amisulpride – Drug Profile

Product Description

Mechanism Of Action

History of Events

AVN-101 – Drug Profile

Product Description

Mechanism Of Action

History of Events

brilaroxazine – Drug Profile

Product Description

Mechanism Of Action

History of Events

DDD-028 – Drug Profile

Product Description

Mechanism Of Action

dimethyltryptamine – Drug Profile

Product Description

Mechanism Of Action

JNJ-18038683 – Drug Profile

Product Description

Mechanism Of Action

LB-102 – Drug Profile

Product Description

Mechanism Of Action

History of Events

LB-102 LA – Drug Profile

Product Description

Mechanism Of Action

LB-104 – Drug Profile

Product Description

Mechanism Of Action

lurasidone hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Antagonize 5 HT7 Receptors for Crohn’s Disease and Ulcerative Colitis – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Target 5-HT7R for Sleep Disorders – Drug Profile

Product Description

Mechanism Of Action

vortioxetine hydrobromide – Drug Profile

Product Description

Mechanism Of Action

History of Events

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) – Dormant Products

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) – Discontinued Products

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) – Product Development Milestones

Featured News & Press Releases

May 03, 2022: Reviva Pharmaceuticals announces update on RECOVER, a pivotal phase 3 global study evaluating brilaroxazine for the treatment of schizophrenia

Apr 26, 2022: Reviva Pharmaceuticals to host key opinion leader webinar on brilaroxazine for schizophrenia and Other neuropsychiatric disorders

Apr 11, 2022: Vortioxetine demonstrates advantage on daily and social functioning vs. desvenlafaxine in a large head-to-head study

Mar 03, 2022: Core One Labs announces successful proof-of-concept for biosynthetic N-methyltryptamine (NMT)

Feb 10, 2022: Core One Labs expects imminent breakthrough to produce NMT, Precursor to DMT

Feb 09, 2022: Sunovion and Otsuka initiate Phase 3 clinical development of non-racemic amisulpride for the treatment of people with bipolar depression

Feb 01, 2022: Reviva Pharmaceuticals announces first patients dosed in pivotal phase 3 study and long-term safety trial evaluating Brilaroxazine for the treatment of schizophrenia

Jan 10, 2022: Reviva Pharmaceuticals Holdings receives FDA may proceed letter for pivotal phase 3 clinical trial and long-term safety trial evaluating Brilaroxazine for the treatment of Schizophrenia

Dec 07, 2021: LB announces presentation of full results of dopamine receptor occupancy study of LB-102 at the 2021 ACNP conference

Oct 04, 2021: LB Pharmaceuticals presents results of dopamine receptor occupancy studies of LB-102 at ECNP conference

Oct 01, 2021: U.S. court issues decision in Trintellix patent litigation upholding active ingredient patent

May 03, 2021: H. Lundbeck: New study finds that vortioxetine helps patients with MDD and comorbid Generalized Anxiety Disorder

May 03, 2021: Sunovion presents data from marketed and late-stage development psychiatric compounds at the American Psychiatric Association (APA) Annual Meeting 2021

Apr 26, 2021: Reviva announces full details of positive phase 2 clinical trial results for acute Schizophrenia

Apr 22, 2021: Vortioxetine significantly improves overall functioning in a global real-world study in Major Depressive Disorder

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Frequently asked questions

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
Immuno-oncology in pharma: neoepitope prediction
$250 | December 2023
Pharmaceuticals
New
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.